loading
Amicus Therapeutics Inc stock is traded at $7.61, with a volume of 3.92M. It is up +0.13% in the last 24 hours and up +22.35% over the past month. Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$7.60
Open:
$7.7
24h Volume:
3.92M
Relative Volume:
0.84
Market Cap:
$2.35B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-22.38
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
+2.84%
1M Performance:
+22.35%
6M Performance:
-17.19%
1Y Performance:
-34.96%
1-Day Range:
Value
$7.58
$7.77
1-Week Range:
Value
$7.28
$7.77
52-Week Range:
Value
$5.51
$12.65

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Name
Name
Amicus Therapeutics Inc
Name
Phone
(609) 662-2000
Name
Address
47 HULFISH STREET, PRINCETON, NJ
Name
Employee
499
Name
Twitter
@amicusrx1
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
FOLD's Discussions on Twitter

Compare FOLD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
FOLD
Amicus Therapeutics Inc
7.61 2.28B 493.67M -104.69M -31.51M -0.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-17-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-13-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-06-24 Initiated Jefferies Buy
May-30-24 Initiated Wells Fargo Overweight
May-14-24 Upgrade Guggenheim Neutral → Buy
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-09-22 Initiated Morgan Stanley Equal-Weight
Apr-13-22 Resumed Goldman Neutral
Jan-14-22 Upgrade SVB Leerink Mkt Perform → Outperform
Nov-15-21 Upgrade Stifel Hold → Buy
Sep-30-21 Upgrade JP Morgan Neutral → Overweight
Jul-19-21 Resumed BTIG Research Buy
May-27-21 Initiated Needham Hold
May-21-21 Initiated UBS Buy
Apr-14-21 Upgrade Cantor Fitzgerald Neutral → Overweight
Mar-02-21 Initiated Stifel Hold
Feb-12-21 Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-12-21 Downgrade JP Morgan Overweight → Neutral
Dec-28-20 Resumed Cantor Fitzgerald Overweight
Dec-10-20 Downgrade Citigroup Buy → Neutral
Nov-11-20 Initiated Berenberg Hold
Jun-17-20 Initiated BTIG Research Buy
Feb-04-20 Resumed Cantor Fitzgerald Overweight
Nov-12-19 Reiterated H.C. Wainwright Buy
Jun-17-19 Initiated H.C. Wainwright Buy
Jun-05-19 Reiterated Cantor Fitzgerald Overweight
Apr-05-19 Initiated Janney Buy
Jan-30-19 Initiated Cantor Fitzgerald Overweight
Oct-29-18 Initiated Citigroup Neutral
Aug-17-18 Downgrade Chardan Capital Markets Buy → Neutral
Oct-06-17 Resumed Goldman Neutral
Sep-13-17 Reiterated Chardan Capital Markets Buy
Aug-10-17 Reiterated Chardan Capital Markets Buy
Jan-24-17 Upgrade Robert W. Baird Neutral → Outperform
May-18-16 Initiated BofA/Merrill Buy
Apr-14-16 Initiated Robert W. Baird Neutral
Apr-12-16 Reiterated Chardan Capital Markets Buy
Sep-16-15 Downgrade Chardan Capital Markets Buy → Neutral
Jun-16-15 Reiterated Chardan Capital Markets Buy
View All

Amicus Therapeutics Inc Stock (FOLD) Latest News

pulisher
Aug 20, 2025

Drawdown in Amicus Therapeutics Inc. May Be Nearing End2025 Risk Factors & Weekly Momentum Stock Picks - newsyoung.net

Aug 20, 2025
pulisher
Aug 20, 2025

Vanguard Group Inc. Sells 208,342 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

Entropy Technologies LP Makes New $317,000 Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat

Aug 20, 2025
pulisher
Aug 19, 2025

Deutsche Bank AG Buys 216,882 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat

Aug 19, 2025
pulisher
Aug 19, 2025

3,522,217 Shares in Amicus Therapeutics, Inc. $FOLD Bought by Nuveen LLC - MarketBeat

Aug 19, 2025
pulisher
Aug 17, 2025

Connor Clark & Lunn Investment Management Ltd. Has $6.42 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Aug 17, 2025
pulisher
Aug 17, 2025

Published on: 2025-08-17 13:52:40 - 선데이타임즈

Aug 17, 2025
pulisher
Aug 16, 2025

What analysts say about Amicus Therapeutics Inc. stock outlook2025 Buyback Activity & Risk Controlled Stock Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Regression analysis insights on Amicus Therapeutics Inc. performanceWeekly Trading Summary & Real-Time Volume Trigger Notifications - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

Can trapped investors hope for a rebound in Amicus Therapeutics Inc.Quarterly Profit Review & AI Powered Market Entry Ideas - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Will earnings trigger a reversal in Amicus Therapeutics Inc.2025 Short Interest & Daily Profit Focused Screening - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Amicus Therapeutics' Pompe Disease Study: A Global Observational Registry. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Amicus Therapeutics Inc. Recovery Likely Here’s What Data ShowsPortfolio Update Report & Daily Technical Stock Forecast Reports - beatles.ru

Aug 15, 2025
pulisher
Aug 14, 2025

What’s the recovery path for long term holders of Amicus Therapeutics Inc.2025 AllTime Highs & Technical Analysis for Trade Confirmation - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Using economic indicators to assess Amicus Therapeutics Inc. potential2025 Technical Overview & Stock Portfolio Risk Management - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Published on: 2025-08-14 05:57:55 - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

What institutional flow reveals about Amicus Therapeutics Inc.2025 Earnings Impact & Expert Approved Momentum Trade Ideas - Newser

Aug 14, 2025
pulisher
Aug 13, 2025

Heatmap Data Shows High Activity in Amicus Therapeutics Inc. Sector [Trade Analysis Summary]Weekly Market Pulse Updates - 선데이타임즈

Aug 13, 2025
pulisher
Aug 12, 2025

Has Amicus Therapeutics Inc. formed a bullish divergenceFree Daily Smart Money Movement Monitor - Newser

Aug 12, 2025
pulisher
Aug 11, 2025

Applying Wyckoff theory to Amicus Therapeutics Inc. stockTrade Alert System with Volume Analysis - Newser

Aug 11, 2025
pulisher
Aug 10, 2025

Why is Amicus Therapeutics Inc. stock going downMassive Profit Potential Picks - mustnews.co.kr

Aug 10, 2025
pulisher
Aug 09, 2025

Amicus Therapeutics (NASDAQ:FOLD) Trading 9.3% HigherShould You Buy? - MarketBeat

Aug 09, 2025
pulisher
Aug 09, 2025

What candlestick patterns are forming on Amicus Therapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

How Efficient Is Amicus Therapeutics Inc. at Controlling Operating CostsFree ROI Boosting Trade Opportunity Calendar - Newser

Aug 09, 2025
pulisher
Aug 07, 2025

Jefferies Financial Group Inc. Invests $1.53 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Aug 07, 2025
pulisher
Aug 07, 2025

Wall Street Zen Upgrades Amicus Therapeutics (NASDAQ:FOLD) to Buy - MarketBeat

Aug 07, 2025
pulisher
Aug 06, 2025

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - Benzinga

Aug 06, 2025
pulisher
Aug 06, 2025

Amicus reiterates $1B sales target for Galafold and Pombiliti/Opfolda by 2028 amid global expansion and Phase III pipeline progress - MSN

Aug 06, 2025
pulisher
Aug 05, 2025

Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy? - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect? - sharewise.com

Aug 05, 2025
pulisher
Aug 05, 2025

Amicus Therapeutics (NASDAQ:FOLD) Upgraded at Wall Street Zen - Defense World

Aug 05, 2025
pulisher
Aug 05, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Position Reduced by Y Intercept Hong Kong Ltd - MarketBeat

Aug 05, 2025
pulisher
Aug 04, 2025

Amicus Therapeutics Inc. Rebound Backed by Sentiment ShiftFundamental + Technical Hybrid Stock Tips Shared - metal.it

Aug 04, 2025
pulisher
Aug 04, 2025

Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Aug 04, 2025
pulisher
Aug 04, 2025

Envestnet Asset Management Inc. Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Aug 04, 2025
pulisher
Aug 04, 2025

Assetmark Inc. Trims Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Aug 04, 2025
pulisher
Aug 04, 2025

XTX Topco Ltd Has $871,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Aug 04, 2025
pulisher
Aug 03, 2025

Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ... By GuruFocus - Investing.com Canada

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Amicus Therapeutics Inc.Invest in stocks with strong fundamentals - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Why is Amicus Therapeutics Inc. stock attracting strong analyst attentionUnlock powerful portfolio management tools - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about Amicus Therapeutics Inc. stockFree Real-Time Stock Data - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Amicus Therapeutics Inc. stock higher in 2025Phenomenal trading returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Amicus Therapeutics Inc. stock expected to show significant growthDiscover stocks with massive upside potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the technical indicators suggesting about Amicus Therapeutics Inc.Get daily expert analysis on top stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - Yahoo Finance

Aug 03, 2025

Amicus Therapeutics Inc Stock (FOLD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Amicus Therapeutics Inc Stock (FOLD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Campbell Bradley L
President and CEO
Feb 19 '25
Sale
10.00
400
4,000
1,150,657
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):